Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis

Journal of Translational Medicine

Samir K Brahmachari¹  Rohit Vashisht² 

[1] CSIR-Institute of Genomics and Integrative Biology, New Delhi, India;CSIR-OSDD Unit, CSIR-IGIB, New Delhi, India

关键词: Metformin;    FDA approved drugs;    Bacterial persistence;    Systems biology spindle map;    Diabeties;    Tuberculosis;   

Others  :  1137511
DOI  :  10.1186/s12967-015-0443-y

 received in 2014-11-21, accepted in 2015-02-18,  发布年份 2015

【 摘 要 】

Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb) remains a global health concern. The evolution of various multi-drug resistant strains through genetic mutations or drug tolerant strains through bacterial persistence renders existing antibiotics ineffective. Hence there is need for the development of either new antibiotics or rationalizing approved drugs that can be utilized in combination with existing antibiotics as a therapeutic strategy. A comprehensive systems level mapping of metabolic complexity in Mtb revels a putative role of NDH-I in the formation of bacterial persistence under the influence of front-line antibiotics. Possibilities of targeting bacterial NDH-I with existing FDA approved drug for type-II diabetes, Metformin, along with existing front-line antibiotics is discussed and proposed as a potential combination therapy for TB.

【 授权许可】

   
2015 Vashisht and Brahmachari; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Tenover FC: Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 2006, 34:S3-10.
• [2]Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S: Bacterial Persistence as a Phenotypic Switch. Science 2004, 305:1622-5.
• [3]Vashisht R, Bhat A, Kushwaha S, Bhardwaj A, Consortium O, Brahmachari S: Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets. J Transl Med 2014, 12:263. BioMed Central Full Text
• [4]Pernicova I, Korbonits M: Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014, 10:143-56.
• [5]Yagi T, Yano T, Di Bernardo S, Matsuno-Yagi A: Procaryotic complex I (NDH-1), an overview. (BBA) - Bioenergetics 1998, 1364:125-33.
• [6]Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-44.
• [7]Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al.: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 2014, 13(3):e02242.
• [8]Singhal A, Jie L, Kumar P, Hong GS, Leow MK-S, Paleja B, et al.: Metformin as adjunct antituberculosis therapy. Sci Transl Med 2014, 6:263ra159.